Kazia Therapeutics Ltd (ASX:KZA) has been selected as a top-10 finalist in the ANZLF Trans-Tasman Innovation and Growth Awards.
The awards are run by the Australia New Zealand Leadership Forum (ANZLF) which brings senior business and government leaders together to help Australia and New Zealand prosper in the global economy.
Innovative programs for brain and ovarian cancer
The company was recognised for its strong growth story, diverse and collaborative culture with its innovative programs for brain and ovarian cancer.
Four winners will receive a unique prize package that includes AUD$20,000 and an exclusive invite to the Accenture’s summit experiences in February and May 2020.
Other finalists include FarmBot Monitoring Solutions, RoboticsPlus, Whispli, Tectonus and AdAlta Ltd.
Late-stage clinical company
Kazia chief executive officer James Garner recently said attaining six clinical trials over the last 12 months showed Kazia had come a long way in a short time.
“Four of our studies are primarily funded by sources external to Kazia, either by the hospitals or by the US National Cancer Institute.
“This support creates enormous leverage for Kazia.”
Kazia is set to become a late-stage clinical company in 2020.